Skip to search formSkip to main contentSkip to account menu

maytansinol

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Trastuzumab is the first humanized monoclonal antibody targeted against the human epidermal growth factor receptor 2 (HER2… 
2012
2012
During impurity analysis of maytansinol (2), produced from the reduction of ansamitocin P‐3 (AP‐3, 1), a surprisingly stable… 
2011
2011
La presente invention a pour objet des intermediaires linker-medicament de Formule I qui sont conjugues a des anticorps pour… 
2006
2006
A process for preparing maytansinol comprising: a) reducing a C3-ester of maytansinol with a reducing hydride reagent with… 
2003
2003
Methods of preparing maytansinol from disulfide-containing maytansinoid esters by reduction with LiAlH The maytansinol is useful… 
Highly Cited
2002
Highly Cited
2002
In an effort to determine the structural requirements for the significant antileukemic, cytotoxic, antitubulin, and antimitotic… 
1996
1996
A total synthesis of maytansinol (1) was achieved, in a convergent way, using (3S,6S,7S)-aldehyde 4 and (S)-p-tolyl sulfoxide 3… 
1986
1986
Maytansinol (1) is the common precursor of maytansinoids (2), which are the 3-0-acyl derivatives of 1 and generally show… 
1984
1984
Several semisynthetic maytansinoids that differ in the structure of the acyl group at the C3 position were prepared by acylation… 
1981
1981
Bacteria, actinomycetes, yeasts, and fungi were screened for their ability to modify the structure of ansamitocins, a group of…